Insilico Medicine’s Chemistry42 Empowers Pan-KRAS Inhibitors of Novel Chemotype (VIDEO)
Caption
Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces the development of novel pan-KRAS inhibitors of new chemotypes through structure-based drug design, scaffold hopping combined with intense molecular modeling, empowered by the generative chemistry methods of Chemistry42, Insilico’s proprietary generative chemistry platform. Developed in the joint efforts of artificial intelligence and human expertise, the candidate compounds demonstrated pan-KRAS inhibition with potency in the upper nanomolar range. The results have been recently published on ACS Medicinal Chemistry Letters.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content